NAPLEX Quiz: Research Ethics

What this quiz covers

This quiz focuses on Research Ethics, giving you a quick way to practice the rules, question types, and explanations that matter most for NAPLEX.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

Question 1

1. Failure to use a double-blind design, which is required for ethical clinical trials
2. Violation of participant safety obligations due to delayed reporting of serious adverse events (correct answer)
3. Overemphasis on confidentiality, which conflicts with the Belmont principle of justice
4. Inappropriate inclusion criteria because hospitalized patients should never be enrolled in research

Explanation: This question addresses the ethical obligation to promptly report serious adverse events in clinical research. The primary ethical concern is the violation of participant safety obligations through delayed reporting of serious bleeding events requiring hospitalization. Option B correctly identifies this as the main issue - delaying reports to the sponsor and ethics committee violates both GCP requirements and the beneficence principle by potentially exposing other participants to preventable harm. Option A is incorrect because double-blinding, while valuable, is not universally required for ethical trials. Option C misunderstands the issue - there's no overemphasis on confidentiality described. Option D is wrong because hospitalized patients can ethically participate in research with appropriate protections. The key principle is that prompt adverse event reporting is a fundamental safety obligation that protects current and future participants by enabling timely risk assessment and protocol modifications.

Question 2

1. Insufficient confidentiality and data-use transparency regarding sensitive genetic information (correct answer)
2. Lack of randomization, which makes pharmacogenomics research unethical under GCP
3. Over-reporting of risks, because genetic studies should minimize discussion of privacy
4. Failure to provide participants with free medication, which is required to meet beneficence

Explanation: This question addresses privacy and confidentiality concerns specific to genetic research data. The primary ethical concern is insufficient transparency about genetic data handling - the consent form fails to address storage, access controls, or potential future uses of sensitive genetic information. Option A correctly identifies this as violating confidentiality principles and data-use transparency requirements for genetic research. Option B is incorrect because randomization isn't required for pharmacogenomics studies. Option C is wrong - discussing privacy risks is essential, not excessive, in genetic research. Option D misunderstands beneficence, which doesn't mandate free medication provision. The key principle is that genetic research requires enhanced consent processes addressing data storage, access, sharing, and future use possibilities, as genetic information has unique privacy implications extending beyond the individual to family members.

Question 3

1. A confidentiality breach because refill access is linked to research participation
2. Undue influence/coercion that compromises voluntary informed consent (respect for persons) (correct answer)
3. Lack of equipoise because the new medication might be better than standard therapy
4. Failure to include a pediatric population, which violates the Belmont principle of justice

Explanation: This question addresses coercion and undue influence in the consent process. The key ethical issue is the threat to move declining patients to the back of the refill line, which constitutes undue influence/coercion that compromises voluntary consent. Option B correctly identifies this violation of the respect for persons principle - true voluntary consent requires freedom from coercion or undue influence. Option A is incorrect because the issue isn't confidentiality but rather the coercive link between participation and pharmacy services. Option C misapplies equipoise, which relates to uncertainty about treatment superiority, not this consent issue. Option D is wrong because justice doesn't mandate pediatric inclusion in all studies. The fundamental principle is that participation must be truly voluntary without threats to withhold or delay standard services, as linking research participation to routine care access is inherently coercive.

Question 4

1. Proceed as written because IRB/ethics committee approval implies the consent content is sufficient
2. Update the consent to clearly disclose reasonably foreseeable risks (including serious risks) and alternatives, then re-consent participants before continued participation (correct answer)
3. Provide the additional risk information only if a participant asks, to avoid influencing enrollment decisions
4. Replace written consent with verbal consent documented by the pharmacist to streamline enrollment in the pharmacy setting

Explanation: This question tests the ethical principle of informed consent, specifically the requirement for comprehensive risk disclosure in research. The key ethical issue is that the consent form fails to disclose serious, reasonably foreseeable risks (respiratory depression) and available alternatives to opioid therapy, which violates the respect for persons principle. Option B is correct because it requires updating the consent to include all material risks and alternatives, then re-consenting participants to ensure their continued participation is truly voluntary and informed. Option A is incorrect because IRB approval does not guarantee consent content is sufficient - investigators must ensure consent documents contain all required elements. Option C violates ethical standards by withholding material risk information unless specifically requested. Option D is inappropriate because replacing written consent with verbal consent does not address the core issue of inadequate risk disclosure and may compromise documentation requirements. The transferable principle is that informed consent must include all reasonably foreseeable risks, especially serious ones, and available alternatives, regardless of IRB approval status.

Question 5

1. Disclose the financial relationship to the institution/IRB and participants, and implement a management plan (e.g., independent consent process) before continuing enrollment (correct answer)
2. Continue the study without disclosure because payments are common and do not affect patient safety
3. Avoid documenting the financial relationship to reduce perceived bias while maintaining GCP records
4. Disclose only to participants after the study ends to prevent influencing their decision to participate

Explanation: This question addresses conflict of interest management in research ethics. The key ethical issue is the undisclosed financial relationship (consulting fees and stock options) between the investigator and the brand manufacturer, which could bias study conduct and participant counseling. Option A is correct because it requires full disclosure to both the institution/IRB and participants, plus implementation of a management plan such as having an independent party conduct the consent process. Option B violates ethical standards by suggesting financial relationships don't matter if common. Option C is unethical as it advocates hiding the conflict rather than managing it transparently. Option D fails to respect participants' autonomy by withholding material information that could affect their enrollment decision. The principle here is that financial conflicts of interest must be disclosed to all relevant parties (institution, IRB, participants) and actively managed to protect research integrity and participant trust.

Question 6

1. Violation of confidentiality through improper safeguarding of identifiable participant information (correct answer)
2. Inadequate randomization of participants to vaccine groups
3. Failure to include a placebo vaccine arm
4. Use of birthdate rather than age in years for analysis

Explanation: The ethical concept being tested is confidentiality in handling research data. The key ethical issue is leaving printed identifiable participant lists in a public area, exposing information to unauthorized viewers and breaching privacy. Choice A is the best identification because it highlights the improper safeguarding that violates GCP standards for data protection. Choice B is incorrect as randomization is not the issue; choice C is suboptimal because placebo arms are not required; choice D is unrelated to confidentiality. The transferable principle is that physical and digital data must be secured to prevent breaches and uphold respect for persons. Under GCP and HIPAA, identifiable information must be stored securely to minimize unauthorized access risks.

Question 7

1. Failure to randomize participants to treatment arms
2. Breach of confidentiality due to insecure handling of identifiable health information (correct answer)
3. Lack of clinical equipoise between the two protocols
4. Inadequate sample size to detect a difference in outcomes

Explanation: The ethical concept being tested is confidentiality in research involving protected health information. The key ethical issue is the breach of confidentiality through emailing unencrypted identifiable data to a personal account, risking unauthorized access and violating participant privacy. Choice B is the best identification because it directly addresses the insecure handling of sensitive information, consistent with GCP and HIPAA requirements for data security. Choice A is incorrect as lack of randomization is not the primary issue here and may not apply to all study designs; choice C is suboptimal because clinical equipoise relates to treatment uncertainty, not data handling; choice D is unrelated to ethics as sample size affects validity but not confidentiality. The transferable principle is that researchers must safeguard identifiable data to uphold respect for persons and nonmaleficence. Under GCP ICH E6 and HIPAA, identifiable health information must be protected through encryption and secure transmission to prevent breaches.

Question 8

1. Breach of confidentiality by sharing identifiable participant information beyond authorized study personnel (correct answer)
2. Failure to dispense the medication in child-resistant packaging
3. Use of adherence as an endpoint rather than sustained virologic response
4. Inability to blind participants to the treatment assignment

Explanation: The ethical concept being tested is confidentiality in research data management. The key ethical issue is uploading photos of identifiable pill bottles to a shared chat accessible to non-study personnel, breaching privacy protections. Choice A is the best identification because it addresses the unauthorized sharing that violates GCP confidentiality standards. Choice B is incorrect as packaging is not the primary concern; choice C is suboptimal because endpoint choice is methodological; choice D is unrelated to confidentiality. The transferable principle is that data access must be limited to authorized personnel to protect privacy. Under GCP and HIPAA, identifiable information must be shared only with approved individuals using secure methods.

Question 9

1. Remove or generalize indirect identifiers and share data only through approved, secure access consistent with the IRB plan (correct answer)
2. Keep the dataset public because direct identifiers (name, MRN) were removed
3. Ask participants after publication if they object to the data sharing
4. Replace the dataset with screenshots to prevent copying while keeping it accessible

Explanation: The ethical concept being tested is data confidentiality and de-identification in research. The key ethical issue is sharing a dataset with indirect identifiers that could enable re-identification, breaching privacy promises. Choice A is the best action because removing or generalizing identifiers and using secure access aligns with GCP and HIPAA standards for protecting confidentiality. Choice B is incorrect as removing direct identifiers alone is insufficient if re-identification is possible; choice C is suboptimal because post-publication consent does not retroactively protect data; choice D is ineffective for preventing breaches. The transferable principle is that data sharing must minimize re-identification risks to uphold respect for persons. Under HIPAA and GCP, de-identified data must exclude 18 identifiers, and sharing requires IRB-approved plans to safeguard privacy.

Question 10

1. Beneficence, because the study failed to minimize harm and maximize possible benefits through safety monitoring (correct answer)
2. Justice, because the study did not recruit equal numbers of men and women
3. Respect for persons, because participants were not paid promptly
4. Fidelity, because the sponsor did not provide free glucose meters

Explanation: The ethical concept being tested is beneficence in research safety monitoring. The key ethical issue is the failure to review hypoglycemia logs promptly, leading to delayed interventions and increased harm. Choice A is the most implicated because beneficence requires minimizing risks and maximizing benefits through vigilant monitoring, as per the Belmont Report. Choice B is incorrect as justice concerns fair selection, not monitoring; choice C is suboptimal because respect for persons does not center on payment timing; choice D is unrelated as fidelity is not a Belmont principle. The transferable principle is that ongoing safety oversight is essential to beneficence. Under GCP ICH E6, protocols must include monitoring plans, and deviations like delayed reviews must be addressed to protect participants.

Question 11

1. Proceed as long as the written consent form contains the risk information, even if it is not discussed
2. Provide a balanced discussion of reasonably foreseeable risks and alternatives, assess understanding, and document consent before enrollment (correct answer)
3. Ask participants to sign a waiver stating they accept unknown risks to simplify the consent process
4. Delay risk disclosure until the first follow-up visit to avoid discouraging enrollment

Explanation: The ethical concept being tested is informed consent in clinical research. The key ethical issue is the investigator's verbal downplaying of risks and omission of important details like driving impairment, which undermines participants' ability to make an informed decision. Choice B is the best action because it ensures a balanced discussion of risks and alternatives, assesses comprehension, and documents consent, aligning with the Belmont Report's respect for persons and GCP requirements for voluntary, informed participation. Choice A is incorrect as it relies solely on written information without verbal reinforcement or assessment, potentially leaving participants uninformed; choice C is suboptimal because waivers for unknown risks do not address known risks and may coerce participation; choice D is unethical as delaying disclosure violates timely information provision and could endanger participants. The transferable principle is that informed consent is an ongoing process requiring full disclosure of foreseeable risks to respect autonomy. Under GCP and 21 CFR 50, consent must include all relevant risk information before enrollment to protect participant welfare.

Question 12

1. To approve marketing language and determine the drug's final labeling
2. To provide independent review of risks/benefits, consent process, and participant protections before research begins (correct answer)
3. To replace the need for informed consent if the study is low risk
4. To guarantee the study will achieve statistically significant results

Explanation: The ethical concept being tested is the role of institutional review boards (IRBs) in research oversight. The key ethical issue is initiating research without prior IRB review, despite plans for publication, which bypasses protections for risks, benefits, and consent. Choice B is the best description because IRBs provide independent ethical review of protocols, including risk-benefit analysis and consent processes, before research begins, as per the Belmont Report and GCP. Choice A is incorrect as IRBs do not approve marketing or labeling, which is FDA's role; choice C is suboptimal because IRBs cannot waive consent entirely for most studies; choice D is unrelated as IRBs do not guarantee statistical outcomes. The transferable principle is that IRB approval ensures ethical soundness and participant protections. Under 21 CFR 56 and GCP ICH E6, all human subjects research intended for generalizable knowledge requires prior IRB approval to safeguard welfare.

Question 13

1. Belmont Report: respect for persons, requiring informed consent that participants can understand (correct answer)
2. Belmont Report: justice, requiring that only English-speaking participants be enrolled to ensure fairness
3. GCP: permitting abbreviated consent if an ethics committee has approved the protocol
4. GCP: prohibiting enrollment of limited English proficiency participants in pharmacy-based research

Explanation: This question tests application of the Belmont Report's respect for persons principle to participants with limited English proficiency. The key ethical issue is enrolling LEP participants using only informal translation of an English consent form, resulting in inadequate understanding of risks. Option A correctly identifies that respect for persons requires informed consent that participants can actually understand, which necessitates proper translation or interpretation services. Option B misinterprets justice - this principle requires fair inclusion, not exclusion of LEP populations. Option C is incorrect because ethics committee approval doesn't permit abbreviated or inadequate consent processes. Option D is wrong as GCP doesn't prohibit LEP participant enrollment but rather requires appropriate accommodations. The principle is that respect for persons demands consent processes adapted to ensure genuine understanding, including professional translation/interpretation for LEP participants, not informal summaries that may omit critical information.

Question 14

1. Data manipulation that misrepresents efficacy, undermining scientific integrity and respect for persons (correct answer)
2. Excessive transparency, because disclosing deviations could confuse readers and participants
3. Failure to provide financial compensation, which is required under the Belmont Report
4. Use of informed consent, which is unnecessary when studying antidepressants in adults

Explanation: This question tests understanding of scientific integrity and data manipulation in research ethics. The primary ethical concern is the selective exclusion of participants with poor response without documenting protocol deviations, which constitutes data manipulation that misrepresents the drug's true efficacy. Option A correctly identifies this as undermining both scientific integrity and respect for persons - participants contributed data expecting honest analysis. Option B is incorrect because transparency about deviations is ethically required, not excessive. Option C is wrong as financial compensation isn't mandated by the Belmont Report. Option D is incorrect because informed consent is always necessary when studying interventions in human subjects. The transferable principle is that all protocol deviations must be documented and all enrolled participants should be accounted for in analysis (intention-to-treat principle), as selective exclusion violates scientific integrity and disrespects participants' contributions.

Question 15

1. To market the study results to prescribers and ensure rapid adoption of the dosing protocol
2. To review and approve the protocol and consent/privacy protections before human subject enrollment begins (correct answer)
3. To replace the need for informed consent by assuming responsibility for participant decisions
4. To guarantee positive outcomes by directing the statistical analysis plan and selecting endpoints

Explanation: This question tests understanding of the ethics committee/IRB's fundamental role in protecting human subjects. The key ethical violation is enrolling participants before obtaining ethics committee approval, which bypasses essential protections for human subjects. Option B correctly identifies the committee's primary role: to prospectively review and approve the protocol, consent forms, and privacy protections before any human enrollment begins. Option A is incorrect because ethics committees don't market results - they protect participants. Option C is wrong because committees don't replace informed consent; they ensure consent processes are adequate. Option D misrepresents the committee's role - they don't guarantee positive outcomes or direct analysis, but rather ensure ethical study conduct. The critical principle is that ethics committee review must occur before enrollment begins, not retroactively, as this prospective review is essential for protecting participant rights and welfare.

Question 16

1. Failure to randomize participants, which violates GCP requirements for human research
2. Inadequate informed consent because observational studies never require consent
3. Breach of confidentiality due to insufficient safeguards for identifiable participant data (correct answer)
4. Lack of a placebo control, which undermines the ethical principle of justice

Explanation: This question tests the ethical principle of confidentiality in research data management. The primary ethical concern is the breach of confidentiality resulting from storing identifiable participant data (names, DOBs, diagnoses) in an unencrypted spreadsheet on a shared drive with broad access, culminating in accidental external disclosure. Option C correctly identifies this confidentiality breach as the main issue, violating both the Belmont principle of respect for persons and GCP data protection requirements. Option A is incorrect because randomization is not required for observational studies. Option B is wrong on two counts: the issue isn't inadequate consent, and observational studies do require consent when collecting identifiable data. Option D is incorrect because placebo controls are not necessary in observational studies and this has no relation to the justice principle. The key principle is that researchers must implement robust safeguards (encryption, access controls, secure storage) to protect participant confidentiality, especially when handling identifiable health information.

Question 17

1. Continue enrollment but remove the "clinically proven" language only, since marketing claims are unrelated to research ethics
2. Disclose and manage the enrollment-based bonus through the institution/IRB (and to participants as required), and revise recruitment materials to avoid undue influence (correct answer)
3. Keep the bonus undisclosed but increase participant compensation to balance the incentive
4. Stop documenting payments to avoid creating records that could bias interpretation of the results

Explanation: This question tests management of multiple conflicts of interest in research. The key ethical issues are the false advertising claim ("clinically proven" for an ongoing trial) and the undisclosed enrollment bonus creating financial conflict of interest. Option B correctly addresses both issues: requiring disclosure and management of the financial incentive through institutional channels and to participants, while revising materials to avoid undue influence through false claims. Option A inadequately addresses only one issue and incorrectly suggests marketing claims are unrelated to research ethics. Option C maintains the unethical non-disclosure while potentially creating additional undue influence through increased payments. Option D advocates for hiding financial relationships, which violates transparency requirements. The principle is that all conflicts of interest - both financial incentives and misleading recruitment materials - must be disclosed and actively managed to protect participant autonomy and research integrity.

Question 18

1. Disclose the consulting relationship to the IRB/institution and implement a management plan (e.g., independent consent taker) (correct answer)
2. Continue without disclosure because consulting is unrelated to study conduct
3. Tell participants the drug is sponsor-recommended to demonstrate transparency
4. Avoid enrolling any participants with severe disease to reduce perceived influence

Explanation: The ethical concept being tested is managing conflicts of interest through disclosure. The key ethical issue is the undisclosed consulting role, which could bias consent discussions and study conduct. Choice A is the best action because disclosing to the IRB and using a management plan like an independent consenter mitigates bias per GCP. Choice B is incorrect as consulting ties can influence judgment; choice C is suboptimal because sponsor recommendations do not disclose conflicts; choice D is unethical as excluding severe cases violates justice. The transferable principle is that dual roles must be disclosed to ensure impartiality. Under 21 CFR 54 and GCP, all financial relationships must be reported for IRB evaluation and management.

Question 19

1. Disclose the financial relationship to the institution/IRB per policy and follow required management steps (correct answer)
2. Continue without disclosure because the payments are not tied to study outcomes
3. Ask participants to waive any right to know about investigator payments
4. Stop documenting adverse events to avoid the appearance of bias

Explanation: The ethical concept being tested is disclosure of financial conflicts of interest. The key ethical issue is failing to report payments from the company, which could bias study conduct despite the investigator's belief otherwise. Choice A is the best action because disclosing to the IRB and following management steps ensures transparency and mitigates influence per GCP. Choice B is incorrect as non-outcome-tied payments still require disclosure; choice C is suboptimal as waivers do not resolve conflicts; choice D is unethical as stopping adverse event documentation violates safety rules. The transferable principle is that all financial ties must be disclosed to maintain integrity. Under 21 CFR 54 and GCP, investigators must report financial interests to sponsors and IRBs for proper management.

Question 20

1. Therapeutic misconception and compromised informed consent due to misleading statements (correct answer)
2. Lack of blinding, which is always unethical in clinical trials
3. Use of standard therapy as a comparator, which violates GCP
4. Failure to include only participants with stage 2 hypertension

Explanation: The ethical concept being tested is therapeutic misconception in informed consent. The key ethical issue is misleading participants about the study's benefits and randomization, fostering a false belief that participation guarantees superior treatment. Choice A is the best identification because such statements compromise voluntary consent and violate respect for persons under the Belmont Report. Choice B is incorrect as blinding is not always required; choice C is suboptimal because standard therapy comparators are ethical; choice D is unrelated to the consent issue. The transferable principle is that consent must clarify research versus treatment to avoid misconception. Under GCP ICH E6, consent forms must explain randomization and alternatives accurately to ensure informed decisions.